Financial toxicity and cancer treatments: Help from biosimilars  – The explanatory case of bevacizumab

Biologics are often high-cost components of oncology care. Biosimilars have the potential to reduce the costs of biologics. Considering that switching treatment from reference product to biosimilar is supported by most available data and post-marketing pharmacovigilance programmes are warranted, it results that biosimilar cancer treatment are not just about the direct cost savings, but also for to incentivise the evaluation and/or clinical use of new treatment approaches and novel drugs. In facts, European Union (EU) guidelines have resulted in the approval of biosimilar therapeutics with comparable efficacy and safety profiles for the recommended indications of their respective reference originator biologics to integrate biosimilars into oncology treatment paradigms and practices.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research